News | February 04, 2022
Lupin Q3FY22 PAT at Rs 545.52 cr.
Lupin has reported consolidated financial results for the period ended December 31, 2021
Lupin has reported consolidated financial results for the period ended December 31, 2021
New instrument helps maximize lab productivity and extends FTIR to large, heavy samples
Fast, flexible space allows clinical trials to start when needed. A trial can become operational, pivot or scale without traditional capital building expenditures
Caplin Point Laboratories has reported consolidated financial results for the period ended December 31, 2021.
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
Medtech plays a vital role in the healthcare system and players in this field believe that the budget should address some of their concerns if India has to become a formidable player
It would be the first protein-based alternative available in Israel
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Subscribe To Our Newsletter & Stay Updated
